GHRL and Anorexia: Pharmacological studies demonstrated that EA treatment at CV12 reduces the levels of plasma monoamine neurotransmitters 5-HT, 5-HIAA, DA, and NE; while simultaneously stimulating the expression of GHRL and NPY to alleviate cisplatin-induced anorexia in rats.